SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature

被引:15
作者
Patoulias, Dimitrios [1 ]
Imprialos, Konstantinos [1 ]
Stavropoulos, Konstantinos [1 ]
Athyros, Vasilios [1 ]
Doumas, Michael [1 ,2 ,3 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp Thessaloniki, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] VAMC, Washington, DC USA
[3] George Washington Univ, Washington, DC USA
来源
CURRENT CLINICAL PHARMACOLOGY | 2018年 / 13卷 / 04期
关键词
SGLT-2; inhibitors; type 1 dabetes mellitus; cardiovascular disease; empagliflozin; dapagliflozin; canagliflozin; ketoacidosis;
D O I
10.2174/1574884713666180807150509
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Sodium-Glucose Cotransporter 2 (SGTL-2) inhibitors are a new class of antidiabetics, which have been approved for the treatment of patients with Type 2 Diabetes Mellitus (T2DM). Besides their beneficial metabolic effects, they exert favourable results in cardiovascular events and risk factors along with renoprotection. However, SGLT-2 inhibitors have not been yet approved as an adjunct therapy to insulin in patients with Type 1 Diabetes Mellitus (T1DM). This review aims at presenting both clinical and experimental data that reinforce the role of SGLT-2 inhibitors as adjunctive treatment in patients with T1DM along with the main restrictions of their use, namely Diabetic Ketoacidosis (DKA). Methods: We conducted a comprehensive research of the relevant literature regarding the off-label use of SGLT-2 inhibitors in clinical practice, presenting the major benefits and the potential risks. Results: SGLT-2 inhibitors are associated with improved glycemic control, reduction in body weight, and decrease in insulin dosage, along with their beneficial cardiovascular and renal effects. However, we cannot overlook the association with increased incidence of DKA events, in the presence of well known predisposing factors. Further investigation is required, in order to establish them as adjunctive treatment in those patients. Conclusion: This novel class of antidiabetics seems to be a very attractive treatment option in patients with T1DM, due to their multiple beneficial effects, but the increased risk of DKA should be taken into account.
引用
收藏
页码:261 / 272
页数:12
相关论文
共 55 条
[1]   SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].
Abdul-Ghani, Muhammad ;
Del Prato, Stefano ;
Chilton, Robert ;
DeFronzo, Ralph A. .
DIABETES CARE, 2016, 39 (05) :717-725
[2]   Factors associated with high levels of glycated haemoglobin in patients with type 1 diabetes: a multicentre study in Brazil [J].
Andrade, Carine Sousa ;
Ribeiro, Guilherme Sousa ;
Souza Teles Santos, Carlos Antonio ;
Silva Neves, Raimundo Celestino ;
Moreira, Edson Duarte, Jr. .
BMJ OPEN, 2017, 7 (12)
[3]   GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM [J].
Argento, Nicholas B. ;
Nakamura, Katherine .
ENDOCRINE PRACTICE, 2016, 22 (03) :315-322
[4]   Effects of dapagliflozin on insulin-requirement, glucose excretion and β-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes [J].
Biester, Torben ;
Aschemeier, Baerbel ;
Fath, Maryam ;
Frey, Marcel ;
Scheerer, Markus F. ;
Kordonouri, Olga ;
Danne, Thomas .
DIABETES OBESITY & METABOLISM, 2017, 19 (11) :1635-1639
[5]   Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis [J].
Birkeland, Kare I. ;
Jorgensen, Marit E. ;
Carstensen, Bendix ;
Persson, Frederik ;
Gulseth, Hanne L. ;
Thuresson, Marcus ;
Fenici, Peter ;
Nathanson, David ;
Nystrom, Thomas ;
Eriksson, Jan W. ;
Bodegard, Johan ;
Norhammar, Anna .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09) :709-717
[6]   The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis [J].
Chen, Jiao ;
Fan, Fang ;
Wang, J. Y. ;
Long, Yang ;
Gao, C. L. ;
Stanton, R. C. ;
Xu, Yong .
SCIENTIFIC REPORTS, 2017, 7
[7]   The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes [J].
Cheng, Sam Tsz Wai ;
Chen, Lihua ;
Li, Stephen Yu Ting ;
Mayoux, Eric ;
Leung, Po Sing .
PLOS ONE, 2016, 11 (01)
[8]   The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Har, Ronnie ;
Fagan, Nora ;
Johansen, Odd Erik ;
Woerle, Hans-Juergen ;
von Eynatten, Maximilian ;
Broedl, Uli C. .
CARDIOVASCULAR DIABETOLOGY, 2014, 13
[9]   Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Maione, Maria ;
Lai, Vesta ;
Lee, Alana ;
Fagan, Nora M. ;
Woerle, Hans J. ;
Johansen, Odd Erik ;
Broedl, Uli C. ;
von Eynatten, Maximilian .
CIRCULATION, 2014, 129 (05) :587-597
[10]   Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [J].
Dandona, Paresh ;
Mathieu, Chantai ;
Phillip, Moshe ;
Hansen, Lars ;
Griffen, Steven C. ;
Tschope, Diethelm ;
Thoren, Fredrik ;
Xu, John ;
Langkilde, Anna Maria .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11) :864-876